

Equality Impact and Risk Assessments

Pan Merseyside Policy Review - Botulinum Toxin A&B

Midlands and Lancashire CSU

Current Status

Stage 1 Draft

Review Date

12/12/2017

Person Responsible

Harinder Sanghera

Service

Policy review for change in commissioning criteria for use of Botulinum Toxin A &B (Botox)

Service Area

Project Lead

Name: O'Brien, Michael
Email: michael.o'brien1@nhs.net
Phone: 07990561572


Explanation

Botox is used to treat a number of disorders characterised by overactive muscle movement, including post-stroke and post-spinal cord injury spasticity, spasms of the head and neck, eyelid, vagina, limbs, jaw, and vocal cords. Similarly, botox is used to relax clenching of muscles and may also be used for improper eye alignment. Botulinum toxin is a neurotoxic protein produced by the bacterium clostridium botulinum and related species. Types A and B are used in medicine to treat conditions including upper motor neurone syndrome, focal hyperhidrosis, blepharospasm, strabismus, chronic migraine and bruxism. It is also widely used in cosmetic treatments. There is a number of botulinum toxin type A products commercially available including Botox, Dysport, and Xeomin. Other brands are available but are only licensed for cosmetic procedures (Allergan). This document is part of the Suite 3 Policy review currently being undertaken by the Pan Merseyside and Cheshire CCG's. The aim of this policy review is to outline current activity across the region from a data perspective; outline the core criteria set across CCG's engaged in the policy review; and capture views on the current policy from an IFR panel perspective. The CCGs that are part of this review are: NHS Halton CCG NHS Liverpool CCG NHS St. Helens CCG NHS South Sefton CCG NHS Southport and Formby CCG NHS Warrington CCG This Stage 1 Assessment has been written by David Partington, MLCSU Equality and Inclusion team.






Assessment




Equality Impact

1	Does this issue plan to withdraw a service, activity or presence?	✘
2	Does this issue plan to reduce a service, activity or presence?	✘
3	Does this issue plan to introduce or increase a charge for Service?	✘
4	Does this issue plan to make a change to a commissioned service?	✘
5	Does this issue plan to introduce, review or change a policy, strategy or procedure?	✘
6	Does this issue plan to introduce a new service or activity?	✘
7	Is this primarily about improving access to, or delivery of a service?	✘
8	Does this affect Employees or levels of training for those who will be delivering the service?	✘
9	Does this issue affect Service users?	✘





10	<p>Can you foresee a negative impact on any Protected Characteristic Group(s)? <i>If YES please state what these could be.</i></p>	






Equality Risk

11	<p>Have you got any general intelligence (research, consultation, etc.)? <i>If YES please list any related documents.</i></p>	
<p>NICE Guidance (TA260): https://www.nice.org.uk/guidance/ta260 NHS Choices: https://www.nhs.uk/conditions/cosmetic-treatments/botulinum-toxin-botox-injections/ https://www.nhs.uk/news/medication/could-botox-be-used-to-treat-severe-asthma/ https://www.nhs.uk/news/2012/03march/pages/botox-for-overactive-bladder-incontinence.aspx</p>		
12	<p>Have you got any specific intelligence (research, consultation, etc.)? <i>If YES please list any related documents.</i></p>	
13	<p>Have you taken specialist advice? (Legal, E&I Team, etc). <i>If YES please state.</i></p>	
<p>Yes: The policy has undergone review with clinicians. The policy group have access to legal advice. The group have access to advice and guidance from Midlands and Lancashire CSU Equality and Inclusion team.</p>		
14	<p>Have you considered your Public Sector Equality Duty? <i>Please provide a rationale.</i></p>	
<p>Yes: The policy review group have considered the potential impact of this policy on staff and patients in line with people with protected characteristics.</p>		
15	<p>Do you plan to publish your information? <i>Include any "Decision Reports"</i></p>	
<p>Yes: Policy and any equality impact assessments will be made available to the public.</p>		

16	<p>Can you minimise any negative effect? <i>Please state how.</i></p>	
<p>Yes: The policy has been subject to engagement work with G.P's.</p>		
17	<p>Do you have any supporting evidence? <i>If YES please list the documents.</i></p>	
<p>Yes: see responses to question 11 and 12.</p>		
18	<p>Have you/will you engage with affected staff and users on these proposals?</p>	
<p>Yes: The policy group has undertaken review of changes within the revised policy. This has involved engagement with G.P's, Service Providers and Clinicians.</p>		

Human Rights Impact

19	<p>Will the policy/decision or refusal to treat result in the death of a person?</p>	
<p>No. Refusal of this treatment should not result in the death of a person.</p>		
20	<p>Will the policy/decision lead to degrading or inhuman treatment?</p>	
<p>No. The policy should not lead to degrading or inhuman treatment.</p>		
21	<p>Will the policy/decision limit a person's liberty?</p>	
<p>No. The policy should not limit a person's liberty.</p>		
22	<p>Will the policy/decision interfere with a person's right to respect for private and family life?</p>	
<p>No. The policy should not interfere with a person's right to respect for private and family life.</p>		

23	Will the policy/decision result in unlawful discrimination?	
No. The policy should not lead to unlawful discrimination. Exceptional cases will be assessed through applications to the Individual Funding Request process.		
24	Will the policy/decision limit a person's right to security?	
No. The policy should not limit a person's right to security.		
25	Will the policy/decision breach the positive obligation to protect human rights?	
No. The policy should not breach human rights.		
26	Will the policy/decision limit a person's right to a fair trial (assessment, interview or investigation)?	
No. The policy should not limit a person's right to a fair trial.		
27	Will the policy/decision interfere with a person's right to participate in life?	
No. The policy should not interfere with a person's right to participate in life.		

Stage 2 Details

Equality Policies
No files uploaded

Equality Other
No files uploaded

Human Rights
No files uploaded

Additional Files
No files uploaded

Comments

Assessment Comment

No comment saved

Approval Comment

No comment saved

Stage 2 Comment

No comment saved

Last Activation Comment

De-activated in error

09/07/2018

mulloy, jennifer

Last Deactivation Comment

Other- Duplicated Stage 1 created in error.

12/03/2018

Partington, David